Abstract 14349: Sacubitril/Valsartan Reduces All-Cause Mortality and Hospitalizations in HFrEF Patients in a Belgian Real-Life Clinical Setting

Introduction: The PARADIGM-HF trial demonstrated that sacubitril/valsartan (S/V) was superior to enalapril in reducing hospitalizations for heart failure, cardiovascular death and all-cause mortali...